William Blair Remains a Hold on Zebra Tech (ZBRA)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Drab covers the Industrials sector, focusing on stocks such as Xometry, Valmont, and Kornit Digital. According to TipRanks, Drab has an average return of 18.4% and a 68.18% success rate on recommended stocks.
In addition to William Blair, Zebra Tech also received a Hold from Morgan Stanley's Meta Marshall in a report issued on May 28. However, today, Robert W. Baird maintained a Buy rating on Zebra Tech (NASDAQ: ZBRA).
ZBRA market cap is currently $14.54B and has a P/E ratio of 27.60.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results
Key Points Eli Lilly, Summit Therapeutics, and Vertex Pharmaceuticals all have important ongoing clinical trials. Shares of these drugmakers could jump if the data from the studies is positive. All three companies have attractive prospects beyond that. 10 stocks we like better than Eli Lilly › Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, long-term investors should have a balanced approach to potentially positive data readouts. Putting aside the fact that it's impossible to predict the outcome of a clinical trial beforehand, even when the results are up to Wall Street's standards, it's hardly worth investing in the company unless there are other good reasons to think it will perform well over long periods. That's why you may want to take a closer look at Eli Lilly (NYSE: LLY), Summit Therapeutics (NASDAQ: SMMT), and Vertex Pharmaceuticals (NASDAQ: VRTX). All three drugmakers should release results from key clinical trials within the next 18 months, and all three have strong prospects for the next five years at least. 1. Eli Lilly In April, Eli Lilly reported positive phase 3 results for its oral GLP-1 candidate, orforglipron. While the market reacted positively to this development, the study in question focused on diabetes patients and used A1c reduction as its primary endpoint. All eyes will be on the company's ongoing late-stage studies for orforglipron in obesity; it should release data from at least one of those clinical trials within the next year. Eli Lilly's work in weight management has taken center stage in the past few years. The pharmaceutical leader could, once again, make a breakthrough by being one of the first to launch a highly effective oral GLP-1 anti-obesity drug. Since current options are administered subcutaneously, you can expect orforglipron to reach a reasonable level of success on the market -- but that's only if it performs well in phase 3 obesity studies. If it fails to do so, Lilly's shares could plunge. Even so, the stock should still be a buy. True, orforglipron would strengthen Lilly's already robust lineup. But even if it falls short of expectations in late-stage studies, the company has several other candidates in development, including retatrutide, which is also in phase 3 trials. Meanwhile, Lilly continues to generate consistent financial results. Revenue and earnings have been growing at a good clip, and that should continue for the foreseeable future. Lastly, Eli Lilly is an excellent dividend growth stock. Although results from phase 3 trials for orforglipron in obesity will be important to monitor, the stock should perform well over the long run, regardless of the outcome of these trials. 2. Summit Therapeutics Summit Therapeutics is developing ivonescimab, a cancer medicine it licensed from Akeso, a China-based biopharma. Ivonescimab is already approved in China; however, Summit needs to conduct clinical trials elsewhere to support approval in the U.S., Europe, and other regions where it holds marketing rights. At least one of these studies will be of particular interest to investors. Summit is testing its crown jewel in a late-stage trial against Merck's Keytruda in patients with non-small cell lung cancer (NSCLC), in a study called Harmoni-3. Enrollment in the study is ongoing, and there is a good chance we'll see top-line data from it by the end of next year. Summit's stock soared when it reported that ivonescimab did better than Keytruda at reducing the risk of recurrence or death in NSCLC patients, in a study conducted in China. However, reproducing this result elsewhere could, once again, jolt the stock price. On the flip side, Summit's share price will move in the wrong direction if the results aren't what Wall Street expects. Should you buy the stock? To me, Summit Therapeutics' prospects for the next five years seem attractive. Ivonescimab is being tested across a range of different cancers, and it looks highly promising in NSCLC, which could be its most important market. Even with the possibility that it may not perform as well in studies outside of China, having already been approved by regulatory authorities in one region reduces the risk of significant clinical and regulatory setbacks. Ivonescimab looks like a potential pipeline in a drug. And if you invest in Summit Therapeutics now, you might reap the benefits of its leading candidate's potential. 3. Vertex Pharmaceuticals Vertex Pharmaceuticals is a proven innovator. The company's strategy is to develop breakthrough medicines where there's a high unmet need. One of Vertex's new targets is type 1 diabetes (T1D). There are no cures for this chronic disease, but the biotech's candidate zimislecel could be a functional cure, in the sense that it could recover patients' ability to produce their own insulin -- something that people with T1D can't do. In the phase 1/2 portion of an ongoing phase 1/2/3 clinical trial, 10 of 12 patients who received zimislecel were insulin-free after a one-year follow-up. All 12 were free of severe hypoglycemic events after 90 days. Vertex should have data from the late-stage portion of this ongoing clinical trial within the next year. Positive results will be well received. The company also aims to submit regulatory applications for this product sometime in 2026. Zimislecel should be a nice addition to Vertex's portfolio. The biotech remains the leader in the market for drugs that treat the underlying genetic causes of cystic fibrosis, a business that is still helping it drive strong revenue and earnings growth. Furthermore, Vertex has added several medicines to its portfolio over the past five years, including Journavx for acute pain and Casgevy for two rare blood-related disorders. Vertex Pharmaceuticals' pipeline also has promising programs beyond zimislecel. Well beyond the announcement of clinical-trial results for this promising T1D therapy, the stock will be in an excellent position to perform. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Merck, Summit Therapeutics, and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. 3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
Trump Media up over 9% after buying hard asset
Trump Media up over 9% after buying hard asset originally appeared on TheStreet. Trump Media & Technology Group or TMTG (Nasdaq: DJT) announced on July 21 that it has added 2 billion worth of Bitcoin to its corporate treasury. Following the announcement, the company's stock surged by more than 8% a day to trade as high as $20.38. President Donald Trump-backed media firm announced the development just days after the House of Representatives passed three major crypto bills to oversee the market structure, stablecoin industry, and anti-CBDC stance. The media firm's latest move aligns with its previously announced Bitcoin treasury strategy plan as it looks to diversify its revenue streams. TMTG controls the social networking app Truth Social, the streaming platform Truth+, and the fintech brand Bitcoin holdings now account for two-thirds of its total liquid assets of roughly $3 billion. Around $300 million has been separately allocated for a bitcoin securities-focused options acquisition roadmap. 'These assets help ensure our Company's financial freedom, help protect us against discrimination by financial institutions,' said Trump Media CEO and President Devin Nunes. He further noted that the company plans to rigorously implement its bitcoin strategy and create a utility token to work across the Truth Social ecosystem in the coming future. Given that Trump is the largest shareholder in TMTG, the company is likely to continue engaging with cryptocurrencies moving forward. On July 8, the company indicated its plan to launch the "Truth Social Crypto Blue Chip". The firm has already submitted a filing regarding the same to the Securities and Exchange Commission (SEC). During his presidential campaign last year, Trump vowed to transform the U.S. into "the crypto capital of the world." The DJT stock was trading at $19.94 at press time. Trump Media up over 9% after buying hard asset first appeared on TheStreet on Jul 21, 2025 This story was originally reported by TheStreet on Jul 21, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 minutes ago
- Yahoo
This Unstoppable Stock-Split Stock -- Which Is Up 700% Since Its IPO -- Could Be the Ultimate Long-Term Buy
Key Points Interactive Brokers operates one of the world's largest online investing platforms for stocks, options, futures, and cryptocurrency. Interactive stock has soared by more than 700% since it went public in 2007, prompting a 4-for-1 stock split last month. That incredible run of performance is likely to continue, based on Interactive's latest operating results. 10 stocks we like better than Interactive Brokers Group › When a company creates a significant amount of value over the long term, its stock price can soar into the hundreds or even thousands of dollars, which makes it difficult for the average retail investor to buy whole shares. But a stock split solves that by increasing the number of shares in circulation, which organically reduces the price per share by a proportionate amount. It doesn't change the underlying value of the company, it just makes the stock more accessible to smaller investors. Interactive Brokers (NASDAQ: IBKR) operates one of the world's largest online investing platforms for stocks, options, futures, and cryptocurrencies. Its stock has gained more than 700% since going public in 2007, and it was recently trading for more than $200. The company executed a 4-for-1 stock split in June, which increased its share count fourfold and reduced its price per share to just $50 at the time. Interactive is likely to continue creating value for investors over the long term, so here's why its stock might be a great buy right now. Interactive is experiencing an influx of new clients Interactive Brokers recently reported its operating results for the second quarter. The company had a record 3.87 million customers at the end of the period, which was a whopping 32% increase from the same time last year. Stock market volatility tends to attract new investors, and the second quarter had that in spades. On April 2, President Donald Trump announced a series of tariffs on America's trading partners, which contributed to a 19% plunge in the S&P 500 (SNPINDEX: ^GSPC) index as investors braced for a global economic slowdown. But by June 30, the president had paused the most aggressive aspects of his new trade policy, which led to a full recovery in the S&P -- and even a new high. The elevated volatility drove a staggering 49% year-over-year increase in Interactive's DARTs (daily active revenue trades) metric during Q2, which means clients were feverishly adjusting their portfolios amid the chaos. Customer equity also surged 34% to a new quarterly high of $664.6 billion by the end of the quarter. This represents the collective value of all the stocks, securities, and cash customers are holding on Interactive's platform. The new all-time high in the S&P 500 (and other market indexes) boosted the customer equity figure, but the influx of new clients was also a tailwind. Interactive earns commissions based on the value of every stock, cryptocurrency, options, and futures transaction executed by its clients, so a higher customer equity figure can directly translate into more revenue for the company. Interactive's commission revenue is growing rapidly Interactive Brokers generated $1.48 billion in total revenue during the second quarter, which was a 20% increase from the year-ago period. The company's revenue has two main components: Commission revenue, which Interactive earns by processing transactions for its clients. This came in at $516 million during the quarter, which was up 27% year over year. Net interest revenue, which is the interest Interactive earns on its own cash reserves, the cash it's holding for its clients, and on margin loans. This came in at $860 million during the quarter, up 9%. There is a third, much smaller component made up of other service fees and income, which came in at $104 million. Interactive's strong commission revenue growth reflects the surge in both trading volume and customer equity in the second quarter. Net interest revenue grew at a more modest pace because interest rates are currently lower than they were a year ago, after the Federal Reserve's three rate cuts near the end of 2024. Analyst expect the Fed to continue cutting rates in 2025 and 2026, which could eventually lead to declines in Interactive's net interest revenue, unless its margin loan book and cash balances climb significantly to offset them. Interactive stock could be a great long-term buy Interactive Brokers is highly profitable, delivering $0.51 in earnings per share (EPS) during the second quarter, representing growth of 24%. The result carried the company's trailing-12-month EPS to $1.94 (adjusted for its recent 4-for-1 stock split). That places its stock at a price-to-earnings (P/E) ratio of 32, which isn't exactly cheap considering the S&P 500 trades at a P/E ratio of 24.7. But the premium valuation might be justified considering the stock has consistently beaten the index since going public in 2007. As I mentioned at the top, Interactive stock is up by more than 700% since then, which translates to a compound annual return of 12.5%. That's better than the average annual return of 10.1% from the S&P 500 during the same period. It's possible Interactive's valuation becomes a barrier to further upside in the short term, but with quarterly customer growth of at least 30% for the past three consecutive quarters, soaring trading volumes, and record client equity, I think its stock is in a great position to continue beating the market over the long term. Thanks to the recent split, investors of all kinds have an opportunity to own one full share. Should you invest $1,000 in Interactive Brokers Group right now? Before you buy stock in Interactive Brokers Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Interactive Brokers Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Interactive Brokers Group. The Motley Fool recommends the following options: long January 2027 $175 calls on Interactive Brokers Group and short January 2027 $185 calls on Interactive Brokers Group. The Motley Fool has a disclosure policy. This Unstoppable Stock-Split Stock -- Which Is Up 700% Since Its IPO -- Could Be the Ultimate Long-Term Buy was originally published by The Motley Fool
